January 2011: PDS signs Collaborative Research and Development Agreement (CRADA) with the NIH’s National Cancer Institute Cancer Vaccine Division. The collaboration will involve development of PDS’s two lead Versamune™-based cancer therapies.

September 2010: PDS Biotechnology awarded NIH grant to develop novel nanocrystal technology. PDS and UNC Chapel Hill have been awarded an STTR grant by the US National Cancer Institute to apply the nanocrystal technology to the delivery of anti-cancer drugs.

September 2010: PDS invited to present at the 10th Annual Biotech in Europe Investor Forum, Zurich, Switzerland. Dr. Bedu-Addo will present the company’s Versamune™ technology and preclinical drug development data at the conference on 09/29/2010.

March 2010: PDS Biotechnology awarded $1.3M NCI contract. PDS has been awarded a $1.3M phase 2 SBIR contract by the US National Cancer Institute to complete studies required for the company’s HPV-cancer drug to be tested in human clinical trials.

September 2009: PDS demonstrates preclinical safety of its HPV-Cancer drug in NCI supported toxicology study. Toxicology, pharmacokinetic, bio-distribution and excretion studies showed no toxicity at the highest doses. The studies also provided further confirmation of efficient uptake of the Versamune™ nanoparticles by the immune system.

Welcome to PDS Biotechnology Corporation

A new generation of simple, safe and effective cures and preventions for cancer and infection

PDS Biotechnology Corporation is a biopharmaceutical company commercializing therapies to treat cancer and infectious diseases based on its proprietary Versamune™ vaccine platform nanotechnology.

Unlike typical vaccines which are only preventative, the patented Versamune™ technology leads to potent curative and preventative immune responses. The nanoparticles facilitate the uptake of disease-associated proteins and peptides by the cells of the immune system and simultaneously activate the immune system to generate a strong and specific immune response against the specific infected cells in the body, resulting in eradication of the cancer or viral disease. Superior prevention and cure of cancer has been demonstrated in head-to-head studies with the leading technologies. In preclinical studies, the company’s two lead Versamune™-based products to treat cancers caused by infection with the HPV virus and melanoma have both demonstrated superior efficacy in causing tumor eradication with low doses of the products. NIH sponsored GLP toxicology studies have also demonstrated a very safe drug profile even at very high doses far exceeding the therapeutic dose.

Curative vaccines have been shown to provide significant potential in treating some of the most debilitating cancers and infectious diseases. However, the current technologies suffer from several drawbacks including high complexity and cost, as well as low potency and safety. The Versamune™ technology provides the solution. PDS’s Versamune™-based therapies provide great potential to revolutionize the treatment of cancer and several infectious diseases.

The first Versamune™-based product, to treat HPV-related cancers is planned to enter human clinical trials in late 2011.

The company's mission is to utilize its proprietary technology to pioneer the development of safe, simple and cost effective vaccines to cure and to prevent specific cancers and infectious diseases for which no effective cures exist.